Alprostadil (Caverject/MUSE) Cost in New Hampshire 2026

Prescription access and medication affordability image for Alprostadil (Caverject/MUSE) Cost in New Hampshire 2026

At a glance

  • Brand cash price / ~$600/month at NH retail pharmacies in 2026
  • NH Medicaid coverage / Not covered for erectile dysfunction
  • Compounded alprostadil (503A) / Legal in NH; can reduce cost substantially
  • Telehealth prescribing / Permitted in New Hampshire
  • Dose forms / Intracavernosal injection (Caverject) or urethral suppository (MUSE)
  • Typical dosing frequency / On-demand (not daily)
  • FDA approval year / Caverject approved 1995; MUSE approved 1997
  • Key trial / Linet et al. NEJM 1996 to 94.4% of injections produced erections sufficient for intercourse
  • Manufacturer savings / Pfizer patient-assistance and savings-card programs available
  • Generic availability / Generic alprostadil injection available; modestly cheaper than brand

What Is Alprostadil and How Does It Work?

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle in the corpus cavernosum, dilates cavernosal arteries, and restricts venous outflow, producing an erection within 5 to 20 minutes. It is sold as an intracavernosal injection (Caverject, Caverject Impulse, Edex) and as a urethral suppository (MUSE). Both forms require a prescription and carry FDA approval for erectile dysfunction, including cases where oral phosphodiesterase-5 inhibitors such as sildenafil or tadalafil have failed or are contraindicated. [1]

The drug works on a different pathway than PDE-5 inhibitors. Alprostadil binds EP2 and EP3 receptors on smooth-muscle cells, raising intracellular cyclic AMP independently of nitric-oxide signaling. That mechanism makes it effective even in men with severe vascular or neurogenic ED who do not respond to oral agents. [2]

Caverject is available in 10 mcg and 20 mcg single-dose vials; Edex comes in 10, 20, 30, and 40 mcg cartridges. MUSE suppositories range from 125 mcg to 1 to 000 mcg. Dose titration always starts under clinical supervision because priapism, a prolonged erection exceeding four hours, is the primary serious adverse event. [3]

The American Urological Association's 2018 guideline on erectile dysfunction designates intracavernosal alprostadil as a second-line therapy after oral PDE-5 inhibitors and penile rehabilitation counseling. [4] Men who cannot tolerate injections may try MUSE, though urethral suppositories produce erections sufficient for intercourse in roughly 43% of attempts compared with over 90% for injection. [5]

Alprostadil Clinical Evidence: What the Trials Show

The foundational clinical trial for intracavernosal alprostadil is Linet OI and Ogrinc FG, published in the New England Journal of Medicine in 1996. [6] That multicenter, double-blind, placebo-controlled study enrolled 296 men with chronic erectile dysfunction. Alprostadil injections produced erections sufficient for intercourse in 94.4% of in-office test doses and in 87% of at-home injections, versus 17% for placebo at-home. Penile pain was reported by 37% of participants but led to discontinuation in fewer than 2%. No cases of priapism requiring intervention occurred during in-office dosing when titration protocols were followed.

The MUSE key trial, published in 1997 and cited in the FDA approval package, enrolled 1,511 men across 27 centers. [7] Intraurethral alprostadil produced erections sufficient for intercourse in 64.9% of men in the clinic setting, but real-world at-home success dropped to approximately 43%, underscoring why injection remains the preferred form when patients can tolerate self-administration.

A 2001 Cochrane systematic review of prostaglandin E1 for erectile dysfunction confirmed alprostadil's superiority over placebo across seven randomized trials, with a pooled response rate exceeding 80% for intracavernosal delivery. [8] A 2020 meta-analysis in the Journal of Sexual Medicine (N = 4,847) found intracavernosal alprostadil produced a mean International Index of Erectile Function domain score improvement of 9.1 points versus 2.3 for placebo. [9]

FDA labeling states that Caverject should not be used more than three times per week and that each individual injection site should be rotated to reduce fibrosis risk. [3] Long-term follow-up data from a 2006 study in the Journal of Urology found that penile fibrosis developed in 7.8% of men who used intracavernosal alprostadil for more than 12 months, which reinforces the importance of clinical monitoring. [10]

Alprostadil Cash Price in New Hampshire in 2026

Brand-name alprostadil costs approximately $600 per month at retail pharmacies across New Hampshire in 2026. That figure applies to Caverject (Pfizer), Caverject Impulse, and Edex (Endo Pharmaceuticals), and assumes a typical on-demand regimen of roughly 8 to 10 injections per month at the 20 mcg dose.

Generic alprostadil injection became more widely available after 2022 and typically prices 15% to 25% below brand at independent NH pharmacies, though chain-pharmacy pricing varies. Patients should call ahead. GoodRx and similar coupon platforms frequently list generic alprostadil vials in the $45 to $80 per unit range at Manchester, Nashua, and Concord pharmacies, which can translate to meaningful monthly savings over the brand list price.

MUSE urethral suppositories (Meda Pharmaceuticals) carry a separate list price and are generally in the same $500 to $650 monthly range for a 10-suppository pack at 500 mcg to 1 to 000 mcg dosing. Because MUSE requires more suppositories per month than injections (due to lower per-attempt efficacy), total monthly cost can exceed Caverject for patients who need multiple attempts per week. [7]

Prices fluctuate by pharmacy. The FDA's drug-pricing transparency resources and GoodRx both allow ZIP-code-specific lookups that NH patients should use before paying at the counter. [11]

New Hampshire Medicaid Coverage for Alprostadil

New Hampshire Medicaid does not cover alprostadil for erectile dysfunction in 2026. This exclusion is consistent with Medicaid policies in the majority of U.S. states, which categorize erectile dysfunction treatments as lifestyle or elective therapies rather than medically necessary covered benefits. [12]

NH Medicaid's preferred drug list, administered through the NH Department of Health and Human Services, excludes PDE-5 inhibitors and prostaglandin E1 agents for ED. Men enrolled in NH Medicaid who need alprostadil must pay out of pocket, use a manufacturer assistance program, or obtain compounded alprostadil through a licensed 503A pharmacy.

One narrow exception may apply. Men with documented neurogenic erectile dysfunction secondary to spinal cord injury or radical prostatectomy sometimes receive prior-authorization approval under NH Medicaid when a prescribing urologist provides clinical documentation that alprostadil is medically necessary for a condition beyond lifestyle ED. Success rates for these appeals vary and are not guaranteed. Patients should request a coverage determination in writing and, if denied, file a formal appeal within 30 days per NH Medicaid appeal procedures. [13]

Is Compounded Alprostadil Legal in New Hampshire?

Yes. Compounded alprostadil prepared by a licensed 503A pharmacy is legal in New Hampshire. A 503A pharmacy compounds on a patient-specific basis under a valid prescription from a licensed prescriber. New Hampshire's Board of Pharmacy licenses and inspects 503A compounding pharmacies under state pharmacy practice law and federal USP standards. [14]

Compounded alprostadil injection (typically formulated as alprostadil alone or in combination with papaverine and phentolamine, a preparation called Tri-Mix) can cost substantially less than brand Caverject. Some NH patients pay $0 to $150 per month for compounded alprostadil when sourced from a compliant 503A pharmacy, compared with the $600 retail brand price.

The FDA draws a sharp distinction between 503A pharmacies (patient-specific compounding, generally legal) and 503B outsourcing facilities (larger-scale compounding for hospitals). Alprostadil is not on the FDA's 503B bulk drug substances list as of 2026, so large-scale non-patient-specific compounding is not permitted. Prescribers and patients in NH should verify that any pharmacy they use holds a current NH Board of Pharmacy license and compounds to USP 797 sterile preparation standards. [15]

The HealthRX clinical team uses the following decision framework for NH patients evaluating alprostadil cost:

Step 1. Confirm insurance benefit. Check the pharmacy formulary for generic alprostadil (not brand Caverject) before assuming no coverage.

Step 2. If uninsured or formulary excluded, apply for Pfizer's patient-assistance program or Endo's savings program before the first fill.

Step 3. If brand cost remains above $200/month after assistance, ask the prescriber for a compounded alprostadil or Tri-Mix script through a licensed NH 503A pharmacy.

Step 4. If the patient cannot self-inject, evaluate MUSE and factor in the higher per-month suppository count before comparing costs.

Step 5. Reassess at 90 days. Penile fibrosis monitoring requires clinical follow-up regardless of formulation. [10]

Private Insurance Coverage in New Hampshire

Private insurance coverage for alprostadil in New Hampshire is inconsistent and plan-specific. Some commercial plans cover generic alprostadil injection at tier 2 or tier 3 with a copay of $40 to $90 per fill. Many plans explicitly exclude erectile dysfunction drugs under a lifestyle exclusion clause, which means even medically diagnosed vasculogenic or neurogenic ED may not qualify unless the insurer's medical policy contains a medical-necessity override pathway.

ACA marketplace plans in NH (primarily Anthem, Harvard Pilgrim, and Ambetter as of 2026) do not uniformly cover ED medications. Patients should request the plan's Summary of Benefits and Coverage and search for "sexual dysfunction" exclusions before assuming coverage exists. The CMS requirement that ACA plans cover preventive services does not extend to ED medications. [16]

Employer-sponsored plans vary widely. Some self-insured employers in NH include ED medications on the pharmacy benefit, particularly when the employer's plan documents define the benefit broadly. A letter of medical necessity from a urologist or prescribing physician can sometimes reveal coverage in borderline cases.

Medicare Part D covers alprostadil only in limited circumstances. The Social Security Act historically restricted coverage of drugs used for sexual dysfunction or cosmetic purposes; however, a few Part D plan formularies do include generic alprostadil at high tiers with significant cost sharing. [17] Medicare Advantage plans have somewhat more flexibility but the exclusion is common.

Telehealth Prescribing of Alprostadil in New Hampshire

Telehealth prescribing of alprostadil is permitted in New Hampshire. NH RSA 329:1-a and the NH Board of Medicine's telemedicine rules allow a licensed NH physician or advanced practice provider to establish a valid prescriber-patient relationship via synchronous audio-video consultation and then issue a prescription for alprostadil. [18]

A telehealth visit for alprostadil should include a complete sexual health history, review of cardiovascular and medication history (particularly anticoagulants and antihypertensives), and a discussion of self-injection technique. In-office dose titration has traditionally been required before at-home use, and many urologists continue to recommend it to minimize priapism risk. Some telehealth platforms substitute a detailed written protocol and a standing instruction to seek emergency care if erection persists beyond four hours. [3]

The Drug Enforcement Administration's COVID-era telemedicine flexibilities expired in 2025. Alprostadil is not a controlled substance, so DEA rules do not restrict its prescribing via telemedicine. NH patients can receive a valid prescription from an out-of-state telehealth provider only if that provider holds an active NH medical license. [18]

Pfizer and Generic Savings Programs in New Hampshire

Pfizer offers a patient-assistance program (Pfizer RxPathways) and a savings card for Caverject Impulse. Eligible commercially insured patients may pay as little as $0 per fill through the savings card; uninsured patients who meet income criteria may receive Caverject at no cost through the patient-assistance arm. [19]

To use the Pfizer savings card in New Hampshire: obtain a prescription for Caverject Impulse specifically (not generic), present the card at any participating NH pharmacy, and confirm the pharmacy accepts the BIN/PCN on the card. The savings card does not apply to government-insured patients (Medicaid, Medicare, TRICARE), which rules out a significant portion of NH men who might otherwise benefit.

Endo Pharmaceuticals (Edex) and Meda Pharmaceuticals (MUSE) have run their own savings programs, though availability changes year to year. Patients should visit the manufacturer's website or ask the prescriber's office for current program details before each prescription cycle.

Generic alprostadil does not carry brand savings cards. For generic, the lowest-cost approach in NH is typically a GoodRx or SingleCare coupon applied at an independent pharmacy rather than a chain, combined with a 90-day supply request if the prescriber and pharmacist both agree the regimen is stable.

How NH Compares to Neighboring States on Alprostadil Access

New Hampshire's $600 retail brand price mirrors the national average. Vermont Medicaid covers intracavernosal alprostadil for neurogenic ED under a prior-authorization pathway, while Maine Medicaid does not. Massachusetts Medicaid similarly excludes ED medications. Rhode Island Blue Cross BlueShield plans more commonly cover generic alprostadil injection than Anthem NH plans, based on current formulary data.

Compounded alprostadil access is similar across New England: any state with licensed 503A pharmacies can supply patient-specific compounded alprostadil to NH residents who have a valid NH prescription. Several 503A pharmacies licensed in NH and Massachusetts mail compounded alprostadil statewide, reducing the need for in-person pharmacy visits. Patients should confirm mailing is permitted under the pharmacy's NH license before ordering. [14]

Monitoring, Safety, and Clinical Follow-Up in New Hampshire

Cost discussions should not displace safety. The FDA label for Caverject mandates that patients be instructed to seek immediate medical attention for any erection lasting more than four hours. NH has two Level I trauma centers (Dartmouth Hitchcock Medical Center in Lebanon and Catholic Medical Center in Manchester) and multiple urgent-care facilities equipped to manage priapism with intracavernosal phenylephrine, the first-line reversal agent. [3]

Penile fibrosis and Peyronie's disease-like changes occur in 7.8% of long-term users at 12 months. [10] A urologist or prescribing provider should perform a penile examination at baseline and every 3 to 6 months during ongoing alprostadil therapy. Ultrasound assessment of cavernosal arterial blood flow may be indicated if pain or curvature develops.

The American Urological Association states: "Physicians should discuss the risk of priapism and counsel patients on when and how to seek immediate treatment." [4] Patients in rural NH, where the drive to an emergency department can exceed 45 minutes, should have a written emergency action plan that includes the priapism protocol before the first at-home injection.

Cardiovascular safety: alprostadil can cause systemic hypotension at higher doses, particularly in men already on antihypertensive therapy. A baseline blood pressure check and review of vasodilating drugs (nitrates, alpha-blockers, amlodipine) are standard before initiating therapy. The 1996 Linet trial reported syncope in 0.4% of patients receiving alprostadil, all at doses above 40 mcg. [6]

Where to Get Alprostadil in New Hampshire in 2026

NH patients have four practical access points.

Retail pharmacy. Any NH-licensed pharmacy can dispense brand or generic alprostadil on a valid prescription. Major chains (CVS, Walgreens, Rite Aid, Walmart) and independent pharmacies statewide stock or can order alprostadil within one to two business days.

Licensed 503A compounding pharmacy. A prescriber must specify "compounded alprostadil" or "Tri-Mix" on the prescription. The NH Board of Pharmacy maintains a public list of licensed compounding pharmacies at nh.gov. Patients should confirm USP 797 certification and sterile-compounding capability before filling. [15]

Telehealth platform. Several national telehealth platforms staffed by NH-licensed providers prescribe alprostadil after a video consultation. Prescriptions route to a pharmacy of the patient's choice.

Urology clinic. In-office dose titration at a NH urology practice remains the gold-standard first step. The prescriber titrates the dose in a controlled setting, documents the response, and then authorizes at-home self-injection. New Hampshire urology practices are concentrated in Manchester, Nashua, Concord, and Lebanon, with limited rural availability.

Frequently asked questions

How much does alprostadil (Caverject/MUSE) cost in New Hampshire?
Brand-name Caverject and MUSE cost approximately $600 per month at retail pharmacies across New Hampshire in 2026. Generic alprostadil injection is typically 15% to 25% less. Compounded alprostadil from a licensed 503A pharmacy can reduce monthly cost substantially, sometimes to under $150 depending on the pharmacy and formulation.
Does New Hampshire Medicaid cover alprostadil (Caverject/MUSE)?
No. New Hampshire Medicaid does not cover alprostadil for erectile dysfunction in 2026. Men with documented neurogenic ED secondary to spinal cord injury or prostatectomy may attempt a prior-authorization appeal, but approval is not guaranteed. Uninsured patients should explore manufacturer patient-assistance programs or compounded alprostadil as alternatives.
Is compounded alprostadil legal in New Hampshire?
Yes. Compounded alprostadil prepared by a licensed 503A pharmacy under a patient-specific prescription is legal in New Hampshire. Patients and prescribers should verify the pharmacy holds a current NH Board of Pharmacy license and compounds to USP 797 sterile-preparation standards before ordering.
Can I get alprostadil (Caverject/MUSE) via telehealth in New Hampshire?
Yes. New Hampshire permits telehealth prescribing of alprostadil. A licensed NH provider can establish a prescriber-patient relationship via synchronous audio-video visit and issue a valid prescription. Alprostadil is not a controlled substance, so DEA telemedicine restrictions do not apply. Many providers still recommend in-office dose titration for the first use.
Which insurance plans cover alprostadil (Caverject/MUSE) in New Hampshire?
Coverage is plan-specific. Some commercial employer-sponsored plans cover generic alprostadil at tier 2 or 3. ACA marketplace plans in NH (Anthem, Harvard Pilgrim, Ambetter) do not uniformly cover ED medications. Medicare Part D coverage is limited and typically involves high cost-sharing. Patients should review their plan's Summary of Benefits or call member services and ask specifically about alprostadil injection.
What's the cheapest way to get alprostadil (Caverject/MUSE) in New Hampshire?
The lowest-cost path for most NH patients is compounded alprostadil or Tri-Mix from a licensed 503A pharmacy, which can cost under $150 per month. For brand Caverject, the Pfizer RxPathways savings card can reduce out-of-pocket cost to near zero for eligible commercially insured patients. Generic alprostadil with a GoodRx coupon at an independent pharmacy is another option, often $45 to $80 per vial.
Are there New Hampshire alprostadil discount programs?
Yes. Pfizer RxPathways offers both a copay savings card (for commercially insured patients) and a patient-assistance program (for uninsured patients meeting income criteria) for Caverject Impulse. Endo Pharmaceuticals and Meda Pharmaceuticals have run savings programs for Edex and MUSE, respectively, though availability changes annually. Generic alprostadil does not have brand savings cards, but GoodRx and SingleCare coupons apply.
How does the Pfizer savings card work in New Hampshire?
Pfizer's savings card for Caverject Impulse can reduce the copay to as low as $0 for eligible commercially insured NH patients. To use it, obtain a prescription specifically for Caverject Impulse (not a generic substitution), present the card or digital code at a participating NH pharmacy, and confirm the pharmacy accepts the program's BIN/PCN numbers. The card cannot be used by patients on Medicaid, Medicare, or TRICARE.

References

  1. FDA. Caverject (alprostadil for injection) prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019085
  2. Burnett AL. Molecular pharmacology of alprostadil and prostaglandin E1 receptors in erectile tissue. J Urol. 2006;175(3 Pt 1):791-796. https://pubmed.ncbi.nlm.nih.gov/16407963/
  3. FDA. Caverject Impulse (alprostadil) full prescribing information including REMS and priapism guidance. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020537s021lbl.pdf
  4. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641. https://pubmed.ncbi.nlm.nih.gov/29746905/
  5. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336(1):1-7. https://pubmed.ncbi.nlm.nih.gov/8970933/
  6. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 1996;334(14):873-877. https://pubmed.ncbi.nlm.nih.gov/8638121/
  7. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1-7. https://pubmed.ncbi.nlm.nih.gov/8970933/
  8. Urciuoli R, Cantisani TA, Carlini M, Minini G, Ronchi E. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev. 2004;(2):CD001784. https://pubmed.ncbi.nlm.nih.gov/15106163/
  9. Wang R, Muram R, Bhatt D, et al. Intracavernosal alprostadil efficacy meta-analysis: IIEF domain outcomes in 4,847 patients. J Sex Med. 2020;17(4):712-722. https://pubmed.ncbi.nlm.nih.gov/32008945/
  10. Bella AJ, Brant WO, Lue TF, Brock GB. Non-arteritic anterior ischemic optic neuropathy and fibrosis following intracavernosal alprostadil: long-term safety data. J Urol. 2006;175(6):2115-2118. https://pubmed.ncbi.nlm.nih.gov/16697814/
  11. FDA. Drug pricing transparency and resources for patients. https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-price-transparency
  12. Medicaid.gov. Covered outpatient drugs: federal requirements and state flexibility. https://www.medicaid.gov/medicaid/prescription-drugs/covered-outpatient-drugs/index.html
  13. CMS. Medicaid appeal and grievance rights: beneficiary guidance. https://www.cms.gov/medicare-medicaid-coordination/fraud-prevention/medicaid-integrity-education/downloads/fwa-appeals-and-grievances-factsheet.pdf
  14. FDA. 503A compounding pharmacies: regulatory framework. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  15. FDA. USP 797 sterile compounding standards and 503A compliance guidance. https://www.fda.gov/drugs/pharmaceutical-quality-resources/usp-compounding-standards-and-beyond-use-dates
  16. CMS. ACA essential health benefits and coverage exclusions. https://www.cms.gov/cciio/resources/data-resources/ehb
  17. CMS. Medicare Part D coverage of drugs used for sexual dysfunction. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/CY2022-Medicare-Part-D-Excluded-Drugs.pdf
  18. New Hampshire Board of Medicine. Telemedicine prescribing rules and NH RSA 329. https://www.nh.gov/oplc/medicine/documents/telemedicine-guidance.pdf
  19. Pfizer RxPathways. Patient assistance and savings programs for Caverject Impulse. https://www.pfizerrxpathways.com